Uprifosbuvir - Merck
Alternative Names: IDX-21437; MK 3682Latest Information Update: 28 Sep 2021
At a glance
- Originator Idenix Pharmaceuticals
- Developer Merck & Co
- Class Antivirals; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-I/II for Hepatitis C in Belgium, Canada (PO) (NCT01974687)
- 28 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Canada, France, Israel, Switzerland, USA, Italy, Puerto Rico (PO) (NCT02332720) (EudraCT2014-003347-35)
- 28 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA (PO) (NCT02759315)